An American subsidiary of pharmaceutical major Cipla has initiated a voluntary recall of certain batches of its generic anti-cancer medication in the United States after manufacturing specifications were not met. The recall, classified as a Class III action by U.S. health regulators, affects more than 400 cartons of Nilotinib capsules available in two dosage strengths. The decision was taken as a precautionary measure following the identification of quality inconsistencies during manufacturing checks.
